Fluorescent In Situ Hybridization Probe Market Report 2026

Fluorescent In Situ Hybridization Probe Market Overview

• Fluorescent In Situ Hybridization Probe market size has reached to $1.68 billion in 2025 • Expected to grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.3% • Growth Driver: Increasing Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To People Preferring Health Technologies • Market Trend: Strategic Collaborations Driving Innovation And Efficiency In FISH Probe Solutions • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Fluorescent In Situ Hybridization Probe Market?

A fluorescent in situ hybridization (FISH) probe refers to a short sequence of single-stranded DNA or RNA that is labeled with a fluorescent dye and designed to bind (hybridize) to a specific complementary DNA or RNA sequence within a cell or tissue sample. This technique allows for the visualization and localization of specific genetic material in chromosomes, nuclei, or tissue sections under a fluorescence microscope. The main types of fluorescent in situ hybridization probes include deoxyribonucleic acid (DNA) probes, ribonucleic acid (RNA) probes, and multiplex probes. Deoxyribonucleic acid (DNA) refers to a molecule that carries the genetic instructions used in the growth, development, functioning, and reproduction of all known living organisms and many viruses. The multiple targets involved are genes and chromosomes, and it uses various technologies, including single-color fluorescence in situ hybridization (FISH), multiplex fluorescence in situ hybridization (FISH), quantitative fluorescence in situ hybridization (FISH), and others. It is applied for clinical diagnostics, research applications, agricultural biotechnology, pharmaceutical research, and genetic research and caters to several end users, such as hospitals and clinics, research laboratories, pharmaceutical companies, and biotechnology companies.

What Is The Fluorescent In Situ Hybridization Probe Market Growth Forecast?

The fluorescent in situ hybridization probe market size is expected to see strong growth in the next few years. It will grow to $2.39 billion in 2030 at a compound annual growth rate (CAGR) of 7.3%. The growth in the forecast period can be attributed to development of multiplex and combinatorial barcoded probes, rising applications in personalized medicine, expansion of pharmaceutical and biotechnology research, increasing regulatory compliance and standardization, integration with ai-driven image analysis and data analytics. Major trends in the forecast period include rising adoption of fish probes in clinical diagnostics, expansion of multiplex and high-throughput screening techniques, increasing use in genetic and agricultural research, integration with advanced imaging and analysis tools, focus on custom probe development for personalized medicine.

Global Fluorescent In Situ Hybridization Probe Market Segmentation

1) By Type: Deoxyribonucleic Acid (DNA) Probes, Ribonucleic Acid (RNA) Probes, Multiplex Probes 2) By Target: Genes, Chromosomes, Other Targets 3) By Technology: Single-Color Fluorescence In Situ Hybridization (FISH), Multiplex Fluorescence In Situ Hybridization (FISH), Quantitative Fluorescence In Situ Hybridization (FISH), Others Technologies 4) By Application: Clinical Diagnostics, Research Applications, Agricultural Biotechnology, Pharmaceutical Research, Genetic Research 5) By End User: Hospitals And Clinics, Research Laboratories, Pharmaceutical Companies, Biotechnology Companies Subsegments: 1) By Deoxyribonucleic Acid (DNA) Probes: Centromeric Probes, Telomeric Probes, Whole Chromosome Paint Probes, Locus-Specific Identifier (LSI) Probes, Comparative Genomic Hybridization (CGH) Probes, Gene Fusion Probes 2) By Ribonucleic Acid (RNA) Probes: mRNA Probes, Long Non-Coding RNA (lncRNA) Probes, MicroRNA (miRNA) Probes, Single-Molecule RNA FISH Probes (smFISH), Circular RNA (circRNA) Probes, Multiplexed Error-Robust FISH (MERFISH) Probes 3) By Multiplex Probes: Multicolor DNA FISH Probes, Multigene Expression Analysis Probes, High-Throughput Screening Probes, Multiplex smFISH Probes, Combinatorial Barcoded Probes, Simultaneous DNA/RNA Detection Probes

What Is The Driver Of The Fluorescent In Situ Hybridization Probe Market?

The increasing adoption of personalized medicine is expected to propel the growth of the fluorescent in situ hybridization probe market going forward. Personalized medicine refers to a medical model that uses information about a person’s genes and lifestyle environment to tailor treatments and healthcare to their specific needs. The increasing adoption of personalized medicine is due to people preferring health technologies that offer real-time monitoring and treatment plans customized to their unique biology. Fluorescent in situ hybridization (FISH) probes support personalized medicine by enabling precise detection of genetic abnormalities at the chromosomal level, thereby guiding tailored therapeutic decisions based on an individual’s unique genetic profile. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the increasing adoption of personalized medicine is driving the growth of the fluorescent in situ hybridization probe industry.

Key Players In The Global Fluorescent In Situ Hybridization Probe Market

Major companies operating in the fluorescent in situ hybridization probe market are Thermo Fisher Scientific Inc., Abbott Laboratories, Oxford Gene Technology IP Limited, Sigma-Aldrich Co. LLC, Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Leica Biosystems Nussloch GmbH, Biocare Medical LLC, Enzo Biochem Inc., LGC Biosearch Technologies, ZytoVision GmbH, Creative Biolabs Inc., Empire Genomics LLC, MetaSystems GmbH, Abnova Corporation, Mirus Bio LLC, Genemed Biotechnologies Inc., Molecular Instruments Inc., Cytocell Technologies Limited.

Global Fluorescent In Situ Hybridization Probe Market Trends and Insights

Major companies operating in the fluorescent in situ hybridization probe market are focusing on developing strategic collaborations to provide access to new markets, technologies, or expertise that may be otherwise difficult or costly to develop alone. Strategic collaboration refers to a planned partnership between two or more entities that work together by combining their strengths and resources to achieve shared long-term goals and mutual benefits. For instance, in April 2025, Empire Genomics, a US-based molecular diagnostics company, collaborated with BioDot, a US-based provider of precision dispensing automation, to launch the BDot Probe Line. The BDot Probe Line offers a distinct solution by providing FISH probes that are pre-optimized for automated systems, addressing a key challenge in clinical cytogenetics and molecular pathology labs. These probes are designed for direct use without the need for manual adjustments, ensuring smooth operation with the Biodot CellWriter S system. This innovation reduces the need for technician intervention, streamlines workflows, and shortens the time to results. The first set of BDot Probe Panels supports FISH analysis for a wide range of blood-related cancers, including MM, MDS, CML, AML, ALL, and other common hematologic conditions.

What Are Latest Mergers And Acquisitions In The Fluorescent In Situ Hybridization Probe Market?

In April 2025, BioDot Inc., a US-based technology company, partnered with Empire Genomics LLC to enhance automation in cytogenetic and molecular diagnostic workflows. With this partnership, BioDot and Empire Genomics aim to streamline laboratory operations by integrating the CellWriter S automated platform with pre-optimized hematology probe panels to deliver greater precision, reduced hands-on time, and improved workflow consistency, ultimately advancing the efficiency and accuracy of genetic analysis. Empire Genomics LLC is a US-based healthcare technology company that specializes in developing molecular diagnostic tools, including FISH probes used for clinical research and genetic testing.

Regional Outlook

North America was the largest region in the fluorescent in situ hybridization probe market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Fluorescent In Situ Hybridization Probe Market?

The fluorescent in situ hybridization probe market consists of revenues earned by entities by providing services such as cancer research, genetic disease detection, and drug development. The market value includes the value of related goods sold by the service provider or included within the service offering. The fluorescent in situ hybridization (FISH) probe market also includes sales of fluorescent dyes, hybridization buffers, detection reagents, control slides, and assay kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.